



GEIS XVI INTERNATIONAL SYMPOSIUM

Fundación VyDA Grant

Fundación VyDA Grant

Jurado

Dr. Winette van der Graaf
The Royal Marsden NHS Foundation Trust
London, UK

Dr. Silvia Stacchiotti
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

Fundación VyDA Grant

Ganador:

Dr. David da Silva Moura

"Exploring vasculature-related targets in angiosarcoma: an open road to new clinical trials"

Puntuación: 147,50/200

Segundo clasificado:

Dr. José Antonio López Guerrero

"Exploration of immunologic tumor microenvironment in soft tissue, visceral and cutaneous Angiosarcomas"

Puntuación: 127,50/200

Tercer clasificado:

Dra. Marta Mendiola

"Farmacological screening in angiosarcoma cellular models for the identification of effective therapies and establishment of new disease models"

Puntuación: 92,50/200



Exploring vasculature-related targets in angiosarcoma: an open road to new clinical trials

Research Team:

David da Silva Moura – Institute of Biomedicine of Seville

Josefina Cruz – University Hospital of Canarias

Carmen Nieves Hernández - University Hospital of Canarias

Nadia Hindi - Institute of Biomedicine of Seville

Miquel Taron - Institute of Biomedicine of Seville

María López Álvarez - Institute of Biomedicine of Seville

Paloma Sánchez Bustos - Institute of Biomedicine of Seville



- Angiosarcomas have very limited therapeutic options;
- Prognostic and predictive biomarkers are an unmet clinical need;
- Angiosarcomas are endothelial-origin tumors, which indicates that new potential vascular therapeutic targets could be relevant in this histology:
 - CD146

Aims

1. To evaluate the expression of several different angiogenesis-related proteins in formalin-fixed, paraffin-embedded (FFPE) tumor samples of angiosarcoma.
2. To correlate clinical data with the expression of these proteins in FFPE tumor samples;
3. To study the effect of gene/ protein knockdown in *in vitro* models of angiosarcoma;
4. To determine genes (potential biomarkers) and pathways modulated by the knockdown of these genes/ proteins;
5. To translate the *in vitro* results to *in vivo* models of angiosarcoma.